William D Chey1, Reema R Mody, Esin Izat. 1. Division of Gastroenterology, University of Michigan Health System, 3912 Taubman Center, Ann Arbor, MI 48109-0362, USA. wchey@umich.edu
Abstract
BACKGROUND: Few studies have explored the satisfaction with proton pump inhibitors (PPIs) for gastroesophageal reflux disease (GERD). AIM: The aim of this study was to assess patient and physician satisfaction with currently prescribed PPIs for patients with GERD. METHODS: Separate online surveys were completed by 1,002 physicians and 1,013 GERD patients. Physician surveys examined satisfaction, symptom relief, long-term therapy, side-effects, breakthrough symptoms, and use of supplemental medications with PPIs. Patient surveys evaluated PPI regimen, length of therapy, satisfaction with PPI, symptom relief, use of supplemental medications, and perceptions about long-term use and side-effects. RESULTS: Most respondents were satisfied with PPI therapy, but 35.4% of GERD patients and 34.8% of physicians perceived patients as "somewhat satisfied" to "completely dissatisfied" with PPI therapy. Patients who were highly satisfied were more likely to indicate complete symptom relief (P < 0.001) relative to patients who were less satisfied. However, over 35% of patients on once-daily and 54% on twice-daily PPI indicated that therapy failed to completely relieve symptoms. Patients who were highly satisfied were more likely to recommend medication to patients with the same symptoms (P < 0.001) and less likely to report that the medication is too expensive (P < 0.001), worry about long-term use (P < 0.001), or add OTC medications for supplemental control (P < 0.004). CONCLUSIONS: Approximately one-third of GERD patients reported persistent symptoms and were dissatisfied with PPI therapy.
BACKGROUND: Few studies have explored the satisfaction with proton pump inhibitors (PPIs) for gastroesophageal reflux disease (GERD). AIM: The aim of this study was to assess patient and physician satisfaction with currently prescribed PPIs for patients with GERD. METHODS: Separate online surveys were completed by 1,002 physicians and 1,013 GERDpatients. Physician surveys examined satisfaction, symptom relief, long-term therapy, side-effects, breakthrough symptoms, and use of supplemental medications with PPIs. Patient surveys evaluated PPI regimen, length of therapy, satisfaction with PPI, symptom relief, use of supplemental medications, and perceptions about long-term use and side-effects. RESULTS: Most respondents were satisfied with PPI therapy, but 35.4% of GERDpatients and 34.8% of physicians perceived patients as "somewhat satisfied" to "completely dissatisfied" with PPI therapy. Patients who were highly satisfied were more likely to indicate complete symptom relief (P < 0.001) relative to patients who were less satisfied. However, over 35% of patients on once-daily and 54% on twice-daily PPI indicated that therapy failed to completely relieve symptoms. Patients who were highly satisfied were more likely to recommend medication to patients with the same symptoms (P < 0.001) and less likely to report that the medication is too expensive (P < 0.001), worry about long-term use (P < 0.001), or add OTC medications for supplemental control (P < 0.004). CONCLUSIONS: Approximately one-third of GERDpatients reported persistent symptoms and were dissatisfied with PPI therapy.
Authors: Robert S Sandler; James E Everhart; Mark Donowitz; Elizabeth Adams; Kelly Cronin; Clifford Goodman; Eric Gemmen; Shefali Shah; Aida Avdic; Robert Rubin Journal: Gastroenterology Date: 2002-05 Impact factor: 22.682
Authors: P Wahlqvist; M Karlsson; D Johnson; J Carlsson; S C Bolge; M-A Wallander Journal: Aliment Pharmacol Ther Date: 2008-02-29 Impact factor: 8.171
Authors: J H Rubenstein; B Nojkov; S Korsnes; S A Adlis; M J Shaw; B Weinman; J M Inadomi; R Saad; W D Chey Journal: Aliment Pharmacol Ther Date: 2007-08-01 Impact factor: 8.171
Authors: Craig S Brown; Brittany Lapin; Chi Wang; Jay L Goldstein; John G Linn; Woody Denham; Stephen P Haggerty; Mark S Talamonti; John A Howington; Joann Carbray; Michael B Ujiki Journal: Surg Endosc Date: 2015-02-13 Impact factor: 4.584